What question did this study set out to answer?

To assess whether prediagnostic use of systemic menopausal hormone therapy influences 5- and 10-year survival outcomes in women aged 50 and older with nonlocalized epithelial ovarian cancer.

June 18, 2022International Journal of CancerOpen Access

Long‐term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study

View Full Paper

Ask AI

Bookmark

Authors

LBLouise BaandrupUniversity of Copenhagen MGMichael GalanakisNovo Nordisk (Denmark)CHCharlotte Gerd HannibalDanish Cancer Society

Discussion

Member takes

Implication

Cohort study reveals higher five-year survival after prediagnostic estrogen therapy in nonlocalized epithelial ovarian cancer, suggesting potential long-term benefits among prior hormone users.

Key Points

To assess whether prediagnostic use of systemic menopausal hormone therapy influences 5- and 10-year survival outcomes in women aged 50 and older with nonlocalized epithelial ovarian cancer.
Nationwide cohort study evaluating all Danish women aged ≥50 years diagnosed with nonlocalized epithelial ovarian cancer between 2000 and 2014 (N = 3,776).
Extracted individual prescription data for systemic estrogen therapy (ET) and estrogen plus progestin therapy (EPT) to compute 5- and 10-year absolute and relative survival probabilities using pseudo-values adjusted for histology, comorbidity, income, and residual disease.
Nonusers of hormone therapy had absolute 5-year and 10-year survival probabilities of 19% and 11%, respectively.
Prediagnostic systemic ET was associated with 1.43 (95% CI: 1.01–2.02) times higher 5-year survival for 3–4 years of use and 1.22 (95% CI: 0.96–1.55) times higher 5-year survival for ≥5 years of use; 10-year increases were not statistically significant.
Prediagnostic EPT for 3–4 years yielded relative survival probabilities of 1.14 (95% CI: 0.85–1.53) at 5 years and 1.38 (95% CI: 0.91–2.08) at 10 years, whereas EPT for ≥5 years showed no survival association.

Cite This Study

Baandrup et al. (2022) studied this question.

synapsesocial.com/papers/6a719366a7fbea1e4408730b https://doi.org/10.1002/ijc.34171

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals higher five-year survival after prediagnostic estrogen therapy in nonlocalized epithelial ovarian cancer, suggesting potential long-term benefits among prior hormone users.